Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

“Driving new prescriptions ... to the completion of Novo Holdings’ $16.5 billion Catalent acquisition in December, Novo Nordisk has purchased three of the CDMO’s production sites, bringing ...

In 2024, on its 100th anniversary, the Novo Nordisk Foundation reached a new milestone, awarding close to DKK 10.1 billion (?1.35 billion) to support nearly 1,800 new projects aimed at improving ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... Novo is working on building new manufacturing sites to combat this, and the closing of the Catalent deal at the end of 2024 that ...

Novo Nordisk has committed billions of dollars to new manufacturing capacity on top of an $11 billion deal to buy three manufacturing sites previously owned by Somerset, N.J.-based Catalent to ...

A caller asked Cramer about Novo Nordisk ... the new generation of obesity drugs; however, the company has lost market share to portfolio holding Eli Lilly due to delays in scaling up production ...

Novo Nordisk is leaving nothing ... “across the entire global value chain from manufacturing of [API] to packaging,” said the company. The new plant will boost capacity for GLP-1 products ...